Redefining Parkinson's disease

Parkinson's Disease: Diagnosis, Motor Symptoms and Non-Motor Features

Volumn , Issue , 2013, Pages 7-19

  Adler, Charles H ^a,b   Stern, Matthew B ^c,d  

^a MAYO CLINIC   (United States)

^b Arizona Parkinson's Disease Consortium ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84957041767     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.13.29     Document Type: Chapter

References (30)

1. Adler CH, Connor DJ, Hentz JG et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov. Disord. 25(5), 642-646 (2010).
2. Beach TG, Adler CH, Sue LI et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 115(4), 445-451 (2008).
3. Dickson DW, Fujishiro H, DelleDonne A et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 115(4), 437-444 (2008).
4. Milber JM, Noorigian JV, Morley JF et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 79, 2307-2314 (2012).
5. Siderowf A, Stern MB. Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann. Neurol. 64(Suppl. 2), S139-S147 (2008).
6. Cookson MR, Bandmann O. Parkinson's disease: insights from pathways. Hum. Mol. Genet. 19(R1), R21-R27 (2010).
7. Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson's disease: a new beginning? Neuroscientist 15, 28-35 (2009).
8. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72(15), 1296-1300 (2009).
9. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24(2), 197-211 (2003).
10. Beach TG, Adler CH, Lue L et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117(6), 613-634 (2009).
11. Ross GW, Abbott RD, Petrovitch H et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov. Disord. 21(12), 2062-2067 (2006).
12. DelleDonne A, Klos KJ, Fujishiro H et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch. Neurol. 65(8), 1074-1080 (2008).
13. Beach TG, Adler CH, Sue LI et al. Multiorgan distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119(6), 689-702 (2010).
14. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is a-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov. Disord. 27, 717-719 (2012).
15. Shannon KM, Keshavarzian A, Mutlu E et al. a-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov. Disord. 27, 709-715 (2012).
16. Maarouf CL, Beach TG, Adler CH et al. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol. Res. 34(7), 669-676 (2012).
17. Brooks DJ, Frey KA, Marek KL et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neurol. 184(Suppl. 1), S68-S79 (2003).
18. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol. 45(5), 577-582 (1999).
19. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56, 173-181 (2004).
20. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70(16, Pt 2), 1411-1417 (2008).
21. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 7(11), 1044-1055 (2008).
22. 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J. Neurol. Sci. 240(1-2), 15-19 (2006).
23. Siderowf A, Jennings D, Eberly S et al. Impaired olfaction and other prodromal features in the Parkinson At-Risk syndrome study. Mov. Disord. 27(3), 406-412 (2012).
24. Marek K, Jennings D, Lasch S et al. The Parkinson progression marker initiative (PPMI). Prog. Neurobiol. 95(4), 629-635 (2011).
25. Pouclet H, Lebouvier T, Coron E et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol. Dis. 45(1), 305-309 (2012).
26. Cersosimo MG, Perandones C, Micheli FE et al. a-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. Mov. Disord. 26(1), 188-190 (2011).
27. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 124(5), 665-680 (2012).
28. Postuma RB, Lanfranchi PA, Blais H, Gagnon JF, Montplaisir JY. Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov. Disord. 25(14), 2304-2310 (2010).
29. Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J. Neurol. Neurosurg. Psychiatry 81(9), 1008-1013 (2010).
30. Ha AD, Jankovic J. Pain in Parkinson's disease. Mov. Disord. 27, 485-491 (2012).